AC Immune ACIU
NASDAQ ACIU
$2.42 -0.08 (-3.20%)
At close: Oct 23, 2026 · 4:00 PM EDT

AC Immune (ACIU) Gains from Sales and Divestitures (2014 - 2025)

Updated

AC Immune (ACIU) posted Gains from Sales and Divestitures of -$18,092 for the year ended Dec 31, 2025.

Analysis

AC Immune (ACIU) Gains from Sales and Divestitures (2014 - 2025) Analysis & Trends

  • The figure for the year ended Dec 31, 2025 stands as the highest annual Gains from Sales and Divestitures since the year ended Dec 31, 2021.
  • Business Quant data shows ACIU's Gains from Sales and Divestitures at $14,227 in the year ended Dec 31, 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 AC Immune 243.32 Mn -195.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 37,535.09
Sep 30, 2025 -37,503.29
Dec 31, 2016 1.12 Mn
Dec 31, 2015 505,266.00
Dec 31, 2014 564,452.48
API Access

AC Immune Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ACIU&period=max&api_key=YOUR_API_KEY